Leflunomide in active rheumatoid arthritis: A prospective study in daily practice

British Journal of Clinical Pharmacology

Volumn 58, Issue 2, 2004, Pages 201-208

  Van Roon, E N ^a,b   Jansen, T L Th A ^a   Mourad, L ^c   Houtman, P M ^a   Bruyn, G A W ^a   Griep, E N ^a   Wilffert, B ^a,b,d   Tobi, H ^b   Brouwers, J R B J ^a,b  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c GGZ Midden Brabant   (Netherlands)

^d UNIVERSITY OF BONN   (Germany)

Author keywords

Leflunomide; Rheumatoid arthritis

Indexed keywords

HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ALOPECIA; ANOREXIA; ANXIETY; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMOGRAPHY; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HOARSENESS; HUMAN; HYPERTENSION; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MOUTH ULCER; MUSCLE CRAMP; NAUSEA; NOCTURNAL ENURESIS; POLYURIA; PRIORITY JOURNAL; PRURITUS; RHEUMATOID ARTHRITIS; SKIN DISEASE; SWEATING; THROMBOCYTOPENIA; TINNITUS; TREMOR; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 3843076529     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02131.x     Document Type: Article

References (31)

1. Breedveld FC, Dayer J-M. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 841-9.
2. Steiner C, Tohidast-Akrad M, Witzmann C, et al. Cytokine Prod Synovial T Cells. Rheumatoid Arthritis 1999; 38: 202-13.
3. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259-66.
4. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Int Med 1999; 159: 2542-50.
5. Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatol 2000; 39: 655-65.
6. Kalden JR, Scott DL, Smolen JS, et al. Improved functional ability in patients with rheumatoid arthritis - longterm treatment with leflunomide versus sulfasalazine. J Rheumatol 2001; 28: 1983-91.
7. Cohen S, Cannon CW, Schiff M, et al. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum 2001; 44: 1984-92.
8. Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42: 1322-8.
9. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Arthritis Rheum 2000; 43: 495-505.
10. Kraan MC, Reece RJ, Barg EC, et al. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 43: 1820-30.
11. Black N. Why we need observational studies to evaluate the effectiveness of health care. Br Med J 1996; 312: 1215-18.
12. Prevoo ML, van Gestel AMT, t Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996; 35: 1101-5.
13. Van Gestel AM, van Prevoo MLL, 't Hof MA, et al. Development and validation of the European League against Rheumatism reponse criteria for rheumatoid arthritis. Arthritis Rheum 1996; 39: 34-40.
14. American Collega of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713-22.
15. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Int Med 1999; 130: 478-86.
16. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602.
17. Harris ED. Rationale for combination therapy of rheumatoid arthritis based on pathophysiology. J Rheumatol 1996; 23(Suppl 44): 2-4.
18. Kremer JM, Genovese MC, Cannon CW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 726-33.
19. Dougados M, Emery P, Lemmel EM, et al. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data. J Rheumatol 2003; 30: 2572-9.
20. van Gestel AM, Anderson J, Van Riel PLCM, et al. ACR ad EULAR improvement criteria have comparabe validity in rheumatoid arthritis trials. J Rheumatol 1999; 26: 705-11.
21. Smolen JS, Breedveld F, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatol 2003; 42: 244-57.
22. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow-up programme in southern Sweden. Ann Rheum Dis 2002; 61: 793-8.
23. Siva C, Eisen SA, Shepherd R, et al. Leflunomide use during the first 33 months after food and drug administration approval: experience with a national cohort of 3,325 patients. Arthritis Rheum 2003; 49: 745-51.
24. Hajidiacos NP, Robinson DB, Peschken CA. Leflunomide in clinical practice: Two-year population-based data with clinical validation. American College of Rheumatology 66th Annual Scientific Meeting; October 25-29, 2002, New Orleans, Louisiana (Abstract).
25. Brault I, Gossec L, Pham T, Dougados M. Leflunomide termination rates in comparison with other DMARDS in rheumatoid arthritis. American College of Rheumatology 66th Annual Scientific Meeting; October 25-29, 2002, New Orleans, Louisiana (Abstract).
26. Wolfe F, Michaud K, Stephenson B, Doyle J. Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate. J Rheumatol 2003; 30: 1725-32.
27. Erra A, Moreno E, Tomas C, et al. Efficacy and safety of leflunomide in rheumatoid arthritis patients. Relationship between adverse drug reactions and loading dose. Ann Rheum Dis 2002; 61 (Suppl 1): 379 (Abstract).
28. Jakez-Ocampo J, Richaud-Patin Y, Simon JA, Llorente L. Weekly dose of leflunomide for the treatment of refractory rheumatoid arthritis: an open pilot comparative study. Joint Bone Spine 2002; 69: 307-11.
29. Jaimes-Hernandez J, Roman MR, Suarez-Otero R, et al. Rheumatoid arthritis treatment with weekly leflunomide: an open-label study. J Rheumatol 2004; 31: 235-7.
30. Population pharmacokinetic report. Leflunomide. Hoechstmarion-Roussel, 1997 December, 1-36.
31. Product monograph. Arava™. (leflunomide). Bridgewater NY, Aventis, 2000, 11-13.